Project Grant R15CA267864
Award Date
8/10/22
Completion Date
7/31/25
Dollars Obligated
$899K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $122,408 to define the roles of sequence-non-specific DNA-binding domains in the assembly and function of mammalian SWI/SNF chromatin remodeling complexes. The research aims to determine how mutations in these DNA-binding domains, which are frequently observed in human cancers and neurodevelopmental disorders, impact the biochemical integrity, catalytic activity, and chromatin targeting of...
This Project Grant award of $487,393.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research on backup DNA repair mechanisms in homologous recombination deficient (HRD) cancers. The research aims to determine the role of key proteins like RAD52, HELQ, and POLQ in backup double-strand break repair pathways when the primary homologous recombination pathway is inactivated in certain cancer types. The goal is to identify...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to understand the mechanisms by which a gene essential for rhabdoid tumor viability regulates chromatin function. The $148,568 award to St. Jude Children's Research Hospital will fund a 2.5-year project starting on Dec 25, 2024. The research aims to elucidate how loss of the target protein disrupts the balance between the SWI/SNF chromatin remodeling complex and the polycomb...
This Project Grant from the National Institutes of Health's National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), provides $900,000 to Midwestern University from September 2022 through August 2025. The grant funds research to characterize novel protein-protein interactions within Polycomb Repressive Complex 1 (PRC1) and investigate their role in the selective assembly of functionally distinct PRC1 complexes. PRC1 epigenetically regulates chromatin and improper...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $581,381 to the Sloan-Kettering Institute for Cancer Research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and cancer development, with the goal of informing more...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $489,527 to Emory University to enhance understanding of genetic variants in the SMARCB1 gene and their functional consequences in cancer biology. The 5-year project, starting January 1, 2025, will conduct deep mutagenesis scanning of SMARCB1 to assess over 99% of potential genetic mutations and study how missense mutations in key binding regions impact the...
This Project Grant award of $780,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program supports research to accurately predict the impact of genetic mutations in the chromatin remodeling enzyme SMARCA4. The award to The Medical College of Wisconsin, Inc. aims to develop new computational tools that can interpret how SMARCA4 mutations affect the 3D structure and function of the protein, in order to improve...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $541,682 to The Trustees of Columbia University in the City of New York for a 5-year period from July 3, 2024 to June 30, 2029. The project aims to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the consequences of these domains following treatment with chemotherapeutic drugs....
This Project Grant award for $527,159 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research to understand the fundamental biological mechanisms underlying the initiation and development of breast cancer in individuals with BRCA1 mutations. The key focus is on examining how DNA damage and aberrant cell fate changes in BRCA1-deficient mammary epithelial cells, particularly luminal progenitor cells, may lead to a...
The National Institute of General Medical Sciences (NIGMS) awarded a $445,000 Project Grant under the Biomedical Research and Research Training (CFDA 93.859) federal grant program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to elucidate the molecular mechanisms of DNA double-strand break repair by homologous recombination, a high-fidelity DNA repair pathway that is critical for suppressing cancer development. Over the 5-year project...